Alkylation chemotherapy: Mechanistic potential and pitfalls

Advances in Genetics Research

Volumn 4, Issue , 2011, Pages 179-196

  Mueser, Timothy C ^a   Williams, Kandace J ^b  

^a UNIVERSITY OF TOLEDO   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877920836     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (93)

1. Reminick G. Nightmare in Bari: The World War II Liberty Ship Poison Gas Disaster and Coverup. 2001, Palo Alto: Glencannon Press.
2. Gilman A. and Philips F.S. The biological actions and therapeutic applications of the chlorethylaines and sulfides. Science 1946. 103:409-415.
3. Chabner B.A., Amrein P.C., Druker B.J., Michaelson M., Mitsiades C.S., Gross P.E., Ryan D.P., Ramachandra S., Richardson P., and Supko J.G., Chapter 51: Antineoplastic Agents, in The Pharmacological Basis of Therapeutics, 11e, Gilman G, Editor. 2006, McGraw Hill.
4. Lawley P. and Thatcher C.J. Methylation of Deoxyribonucleic Acid in Cultured Mammalian Cells by N-Methyl-N'-nitro-N-nitrosoguanidine. Biochem. J. 1970. 116:693-707.
5. Ludlum D.B. DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mut. Research 1990. 233:117-126.
6. Fischhaber P.L., Gall A.S., Duncan J.A., and Hopkins P.B. Direct Demonstration in Synthetic Oligonucleotides that N,N'-Bis(2-chloroethyl)-nitrosourea Cross-Links N1 of Deoxyguanosine to N3 of Deoxycytidine on Opposite Strands of Duplex DNA. Cancer Res. 1990. 59:4363-4368.
7. Golding S.E., Rosenberg E., Neill S., Dent P., Povirk L.F., and Valerie K. Extracellular Signal-Related Kinase Positively Regulates Ataxia Telangiectasia Mutated, Homologous Recombination Repair and the DNA Damage Response. Cancer Res. 2007. 67:1046-1053.
8. Knipscheer P., Raschle M., Smogorzewska A., Enoiu M., Vinh Ho T., Scharer O., Elledge S.J., and Walter J.C. The Fanconi Anemia Pathway Promotes Replication-Dependent DNA Interstrand Cross-Link Repair. Science 2009. 326:1698-1700.
9. Wyatt M.D. and Pittmann D.L. Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. Chem. Res. Toxicol. 2006. 19:1580-1594.
10. Blans P. and Fishbein J.C. Determinants of Selectivity in Alkylation of Nucleosides and DNA by Secondary Diazonium Ions: Evidence for, and Consequences of, Preassociation Mechanims. Chem. Res. Toxicol. 2004. 17:1531-1539.
11. Tentori L. and Graziani G. Recent Approaches to Improve the Antitumor Efficacy of Temozolomide. Current Medicinal Chem. 2009. 16:245-257.
12. Jenkins G., Doak S., Johnson G., Quick E., Waters E., and Parry J. Do dose response thresholds exist for genotoxic alkylating agents? Mutagenesis 2005. 20:389-398.
13. Friedberg E.C., Walker G.C., Siede W., Wood R.D., Schultz R.A., and Ellenberger T., DNA Repair and Mutagenesis. 2nd ed. 2006, Washington, D.C.: ASM Press.
14. Fortini P., Pascucci B., Parlanti E., D'Errico M., Simonelli V., and Dogliotti E. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie 2003. 85(11):1053-71.
15. Fishel M.L. and Kelley M.R. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventative target. Molecular Aspects of Medicine 2007. 28:375-395.
16. Chan K.K., Zhang Q.-M., and Dianov G.L. Base excision repair fidelity in normal and cancer cells. Mutagenesis 2006. 21:173-178.
17. Fortini P. and Dogliotti E. Base damage and single-strand break repair: Mechanisms and functional significance of short- and long-patch repair subpathways. DNA Repair 2007. 6:398-409.
18. Daniels D., Woo T., Luu K., Noll D., Clarke N., Pegg A., and Tainer J. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat. Struct. Mol. Biol. 2004. 11:714-720.
19. Gerson S.L. MGMT: it's role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004. 4:296-307.
20. Margison G., Povey A., Kaina B., and Santibanez K., MF. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003. 24:625-635.
21. Warran J.J., Forsberg L.J., and Beese L.S. The structural basis for mutagenicity of O6-methyl-guanine lesions. PNAS 2006. 103:19701-19706.
22. Karran P. and Hampson R. Genomic Instability and Tolerance to Alkylating Agents. Cancer Surveys 1996. 28:69-85.
23. Tomita-Mitchell A., Kat A.G., Marcelino L.a., Li-Sucholeiki X.-C., Goodluck-Griffith J., and Thilly W.G. Mismatch repair deficient human cells: spontaneous and MNNG-induced mutational spectra in the HPRT gene. Mut Research 2000. 450:125-138.
24. Dosch J., Christmann M., and Kaina B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 1998. 19(4):567-573.
25. Jiricny J. The multifaceted mismatch-repair system. Nature Reviews Molecular Cell Biology 2006. 7(5):335-347.
26. Wang Y. and Qin J. MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc. Natl. Acad. Sci. U.S.A. 2003. 100:15387-15392.
27. Yoshioka K.-I., Yoshioka Y., and Hsieh P. ATR kinase activation mediated by MutSa and MutLa in response to cytotoxic O6-methylguanine adducts. Molecular Cell 2006. 22:501-510.
28. Iyer R.R., Pluciennik A., Burdett V., and Modrich P. DNA Mismatch Repair: Functions and Mechanisms. Chem. Rev. 2006. 106:302-323.
29. York S.J. and Modrich P. Mismatch Repair-dependent Iterative Excision at Irreparable O6Methyl guanine Lesions in Human Nuclear Extracts. J. Biol. Chem. 2006. 281(32):22674-22683.
30. Hirose Y., Katayama M., Stokoe D., Haas-Kogan D.A., Berger M.S., and Pieper R.O. The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents. Mol. Cell Biol. 2003. 23:8306-8315.
31. Schroering A.G., Kothandapani A., Patrick S.M., Kaliyaperumal S., Sharma V.P., and Williams K.J. Prolonged cell cycle response of HeLa cells to low-level alkylation exposure. Cancer Res. 2009. 69:6307-6314.
32. Stojic L., Mojas N., Cejka P., di Pietro M., Ferrari S., Marra G., and Jiricny J. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes. and Develop. 2004. 18:1331-1344.
33. Tominaga Y., Tsuzuki T., Shiraishi A., Kawate, H., and Sekiguchi M. Alkylation-induced apoptosis of embryonic stem cells in which the gene for DNA-repair, methyltransferase, has been disrupted by gene targeting. Carcinogenesis 1997. 18(5):889-896.
34. Frouin I., Montecucco A., Spadari S., and Maga G. DNA replication: a complex matter. EMBO reports 2003. 4:666-670.
35. Leonhardt H., Rahn H.-P., Weinzierl P., Sporbert A., Cremer T., Zink D., and Cardoso M.C. Dynamics of DNA Replication Factories in Living Cells. J. Cell Biol. 2000. 149:271-279.
36. Schroering A.G., Edelbrock M.A., Richards T.J., and Williams K.J. The cell cycle and DNA mismatch repair. Exp. Cell Res. 2007. 313:292-304.
37. Weidtkamp-Peters S., Rahn H.-P., Cardoso M.C., and Hemmerich P. Replication of centromeric heterochromatin in mouse fibroblasts takes place in early, middle, and late S phase. Histochem. Cell Biology 2006. 125:91-102.
38. Schroering A.G. and Williams K.J. Rapid induction of chromatin-associated DNA mismatch repair proteins after MNNG treatment. DNA Repair 2008. 7:951-969.
39. Hickman M.J. and Samson L.D. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl. Acad. Sci. USA 1999. 96(19):10764-9.
40. Stojic L., Brun R., and Jiricny J. Mismatch repair and DNA damage signaling. DNA Repair 2004. 3:1091-1101.
41. Schofield M.J. and Hsieh P. DNA Mismatch Repair: Molecular Mechanisms and Biological Function. Annu. Rev. Microbiol. 2003. 57:579-608.
42. Choi J.-Y., Chowdhury G., Zang H., Angel K.C., Vu C.C., Peterson L.A., and Guengerich F.P. Translesion Synthesis across O6-Alkyl guanine DNA Adducts by Recombinant Human DNA Polymerases. J. Biol. Chem. 2006. 281(50):38244-38256.
43. Roos W.P., Tsaalbi-Shtylik A., Tsaryk R., Guvercin F., de Wind N., and Kaina B. The Translesion Polymerase Rev3L in the Tolerance of Alkylating Anticancer Drugs. Mol. Pharmacol. 2009. 76:927-934.
44. Mojas N., Lopes M., and Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes. and Develop. 2007. 21:3342-3355.
45. Ho E.L.Y., Parent M., and Satoh M. Induction of Base Damages Representing a High Risk Site for Double-Strand DNA Break Formation in Genomic DNA by Exposure of Cells to DNA Damaging Agents. Journal of Biological Chemistry 2007. 282(30):21913-21923.
46. Lomax M.E., Cunniffe S., and O'Neill P. Efficiency of repair of an abasic site within DNA clustered damage sites by mammalian cell nuclear extracts. Biochemistry 2004. 43(34):11017-26.
47. Kozmin S.G., Sedletska Y., Reynaud-Angelin A., Gasparutto D., and Sage E. The formation of double-strand breaks at multiply damaged sites is driven by the kinetics of excision/incision at base damage in eukaryotic cells. Nucleic Acids Res. 2009. 37:1767-1777.
48. Roos W.P., Quiros S., Naumann S.C., Kiedron O., Zdzienicka M.Z., and Kaina B. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCE's. DNA Repair 2009. 8:72-86.
49. Zhang H., Marra G., Jiricny J., Maher V., and McCormick J. Mismatch repair is required for O(6)-methylguanine-induced homologous recombination in human fibroblasts. Carcinogenesis 2000. 21:1639-1646.
50. Zhang H., Tsujimura T., Bhattacharyya N., Maher V., and McCormick J. O6-methylguanine induces intrachromosomal homologous recombination in human cells. Carcinogenesis 1996. 17:2229-2235.
51. Lundin C., North M., Erixon K., Walters K., Jenssen D., Goldman A., and Helleday T. Methyl methanesulfonate (MMS) produces heat-labile DNA damage but no detectable in vivo DNA double-strand breaks. Nucleic Acids Res. 2005. 33:3799-3811.
52. Tsaryk R., Fabian K., Thacker J., and Kaina B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Letters 2006. 239:305-313.
53. Worrillow L.J. and Allan J.M. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene 2006. 25:1709-1720.
54. Cejka P. and Jiricny J. Interplay of DNA Repair Pathways Controls Methylation Damage Toxicity in Saccharomyces cerevisiae. Genetics 2008. 179:1835-1844.
55. Sharma S., Salehi F., Scheithauer B.W., Rotondo F., Syro L.V., and Kovacs K. Role of MGMT in Tumor Development, Progression, Diagnosis, Treatment and Prognosis. Anticancer Research 2009. 29:3759-3768.
56. Augustine C.K., Yoo J.S., Potti A., Yoshimoto Y., Zipfel P.A., Friedman H.S., Nevins J.R., Ali-Osman F., and Tyler D.S. Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma. Clin. Cancer Res. 2009. 15:502-510.
57. Esteller M., Gianluca G., Goodman S.N., Zagonel V., Capello D., Botto B., Rossi D., Gloghini A., Vitolo U., Carbone A., Baylin S.B., and Herman J.G. Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients with Diffuse Large B-Cell Lymphoma. J. Natl. Cancer Inst. 2002. 94:26-32.
58. Stiefel M.F. and Grady M.S. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000. 343:1350-1354.
59. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005. 352(997-1003).
60. Helleday T., Petermann E., Lundin C., Hodgson B., and Sharma R.A. DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 2008. 8:193-204.
61. Khan O. and Middleton M.R. The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors. Expert Opin Investig Drugs 2007. 16:1573-1584.
62. Alonso M.M., Gomez-Manzano C., Bekele B.N., Yung W.K.A., and Fueyo J. Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase Promoter. Cancer Res. 2007. 67:11499-11504.
63. Del Rowe J.D., Bello J., Mitnik R., Sood B., Filippi C., Moran J., Freeman K., Mendez F., and Bases R. Accelerated Regression of Brain Metastases in Patients Receiving Whole Brain Radiation and the Topoisomerase II Inhibitor, Lucanthone. Int. J. Radiat. Oncol. Biol. Phys. 1999. 43:89-93.
64. Madhusudan S., Smart F., Shrimpton P., parsons J.L., Laurence G., Houlbrook S., Talbot D.C., Dianov G.L., and Hickson I.D. Isolation of a small molecule inhibitior of DNA base excision repair. Nucleic Acids Res. 2005. 33:4711-4724.
65. Fishel M.L., He Y., Smith M.L., and Kelley M.R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res. 2007. 13:260-267.
66. McNeill D.R., Lam W., DeWeese T.L., Cheng Y.-C., and Wilson I., D.M. Impairment of APE1 Function Enhances Cellular Sensitivity to Clinically Relevant Alkylators and Antimetabolites. Mol. Cancer Res. 2009. 7:897-906.
67. Wang D., Luo M., and Kelley M.R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 2004. 3:679-686.
68. Bobola M.S., Blank A., Berger M.S., Stevens B.A., and Silber J.R. Apurinic/apyrimidinic endonuclease activity is elevated in human gliomas. Clin. Cancer Res. 2001. 7(3510-3518).
69. Evans A.R., Limp-Foster M., and Kelley M.R. Going Ape over Ref-1. Mutat. Res. 2000. 461:83-108.
70. Trivedi R.N., Almeida K.L., Forsaglio J.L., Schamus S., and Sobol R.W. The Role of Base Excision Repair in the Sensitivity and Resistance to Temozolomide-Mediated Cell Death. Cancer Res. 2005. 65(14):6394-6400.
71. Kinsella T.J. Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers. Clin. Cancer Res. 2009. 15:1853-1859.
72. Fisher A.E., Hochegger H., Takeda S., and Caldecott K.W. Poly(ADP-ribose)polymerase 1 accelerates single-strand break repair in concert with Poly(ADP-ribose) glycohydrolase. Mol. Cell Biol. 2007. 27:5597-5605.
73. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005. 434:913-917.
74. Farmer H., McCabe N., Lord C.J., Tutt A.N.J., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Ian H., Knights C., Martin N.M.B., Jackson S.P., Smith G.C.M., and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005. 434:917-921.
75. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. British Medical Bulletin 2009. 89:23-40.
76. Kim M.Y., Zhang T., and Kraus W.L. Poly(ADP-ribosyl)ation by PARP-1: 'PARlaying' NAD+ into a nuclear signal. Genes. and Develop. 2005. 19:1951-1967.
77. Jaiswal A.S., Banerjee S., Panda H., Bulkin C.D., Izumi T., Sarkar F.H., Ostrov D.A., and Narayan S. A Novel Inhibitor of DNA Polymerase B Enhances the Ability of Temozolomide to Impair the Growth of Colon Cancer Cells. Mol. Cancer Res. 2009. 7:1973-1983.
78. Stachelek G.C., Dalal S., Donigan K.A., Hegan D.C., Sweasy J.B., and Glazer P.M. Potentiation of Temozolomide Cytotoxicity by Inhibition of DNA Polymerase B Is Accentuated by BRC2 Mutation. Cancer Res. 2010. 70:409-417.
79. Tang J.-b., Goeliner E.M., Wang X.-h., Trivedi R.N., St. Croix C.M., Jelezcova E., Svilar D., Brown A.R., and Sobol R.W. Bioenergetic Metabolites Regulate Base Excision Repair-Dependent Cell Death in Response to DNA Damage. Mol. Cancer Res. 2010. 8:67-78.
80. Andrabi S.A., Kim N.S., Yu S.W., Wang H., Koh D.W., Sasaki M., Klaus J.A., Otsuka T., Zhang Z., Koehler R.C., Hurn P.D., Poirier G.G., Dawson V.L., and Dawson T.M. Poly(ADP-ribose) (PAR) polymer is a death signal. PNAS 2006. 103:18308-18313.
81. Heeres J.T. and hergenrother P.J. Poly(ADP-ribose) makes a date with death. Curr Opin. Chem. Biol. 2007. 11:644-653.
82. Marra G. and Boland C.R. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and the historical perspectives. J. Natl. Cancer Inst. 1995. 87:1114-1125.
83. Casorelli I., Offman J., Mele L., Pagano L., D'Errico M., Sica S., Giannini G., Leone G., Bignami M., and Karrran P. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair 2003. 2:547-559.
84. Karran P., Offman J., and Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 2003. 85:1149-1160.
85. Taverna P., Liu L., Hanson A.J., Monks A., and Gerson S.L. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol. 2000. 46:507-516.
86. Yip S., Miao J., Cahill D.C., Iafrate A.J., Aldape K., Nutt C.L., and Lous D.N. MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. Clin. Cancer Res 2009. 15:4622-4629.
87. Takata K., Shimizu T., Iwai S., and Wood R.D. Human DNA Polymerase r (POLr) Is a Low Fidelity Enzyme Capable of Error-Free Bypass of 5S-Thymine Glycol. J. Biol. Chem. 2006. 281:23445-23455.
88. Lin D.P., Wang Y., Scherer S.J., Clark A.B., Yang K., Avdievich E., Jin B., Werling U., Parris T., Kurihara N., Umar A., Kucherlapati R., Lipkin M., Kunkel T.A., and Edelmann W. An Msh2 Point Mutation Uncouples DNA Mismatch Repair and Apoptosis. Cancer Res. 2004. 64:517-522.
89. Yang G., Scherer S.J., Shell S.S., Yang K., Kim M., Lipkin M., Kucherlapati R., Kolodner R.D., and Edelmann W. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004. 6:139-150.
90. Iglehart J.D. and Silver D.P. Synthetic Lethality - A New Direction in Cancer-Drug Development. N. Engl. J. Med. 2009. 361:189-191.
91. Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., Dooling D., Dunford-Shore B.D., McGrathe S., Hickenbotham M., Cook L., Abbott R., Larson D.E., Koboldt D.C., Pohl C., SMith S., Hawkins A., Abbott S., Locke D., LaDeana W.H., Miner T., Fulton L., Magrini V., Wylie T., Glasscock J., Conyers J., Sander N., Shi Z., Osborne J.R., Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., Wetervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., DiPersia J.F., and Wilson R.K. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008. 456:66-72.
92. Ocak S., Sos M.L., Thomas R.K., and Massion P.P. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur. Respir. J. 2009. 34:489-506.
93. Overdevest J.B., Theoderescu D., and Lee J.K. Utilizing the Molecular Gateway: The Path to Personalized Cancer Management. Clinical Chemistry 2009. 55:684-697.